For research and educational purposes only · Not medical advice · Consult a qualified physician before any human use
Pancragen (Lys-Glu-Asp-Trp, KEDW) is the pancreas-targeted member of the Khavinson bioregulator family, making it uniquely distinctive in this series: it has published indexed human clinical data. A 2011 study in 33 elderly type 2 diabetes patients reported significant fasting glucose reduction, improved glucose tolerance, and reduced insulin resistance index, with no equivalent changes in untreated comparators. Rhesus monkey studies (2014, 2015) demonstrated glucose normalization and improved C-peptide dynamics comparable to glimepiride. Cell culture studies show activation of key pancreatic differentiation transcription factors. No randomized controlled trial has been published, and all human data originate from one institution. The glucose-lowering signal is real enough to warrant serious caution about combining Pancragen with existing antidiabetic medications without medical supervision.
Pancragen is a research compound with no FDA or EMA approval. However, uniquely among the Khavinson bioregulators, it has one published indexed human study: Korkushko et al. (2011, Bulletin of Experimental Biology and Medicine) enrolled 30 healthy elderly and 33 elderly patients with type 2 diabetes. In the DM2 group, Pancragen significantly decreased fasting glucose, improved oral glucose tolerance test results, and reduced plasma insulin and the insulin resistance index. The study had no control arm for Pancragen itself (the comparator was the absence of change in untreated DM2 patients, not a placebo group), was unblinded, and originated from the same institutional ecosystem as all Pancragen research. This is not a randomized controlled trial.
A critical safety implication follows directly from this data: if Pancragen produces genuine glucose-lowering effects in elderly type 2 diabetes patients, it has the potential to cause hypoglycemia when combined with antidiabetic medications including insulin, sulfonylureas, GLP-1 agonists, or metformin. Any person with diabetes considering Pancragen must do so under medical supervision with blood glucose monitoring. The 2011 study was conducted in elderly patients already managing type 2 diabetes; the Pancragen was not used as monotherapy as a substitute for established treatment.
A naming disambiguation is important: Pancragen (the Khavinson tetrapeptide, KEDW) is entirely different from PancraGEN, a genetic risk assessment test for pancreatic cancer developed by Interpace Biosciences. These are unrelated products with similar names. Any marketing or clinical reference to PancraGEN diagnostic results should not be conflated with Pancragen the peptide bioregulator.
All primary Pancragen research originates from the St. Petersburg Institute of Bioregulation and Gerontology and closely affiliated groups (Institute of Gerontology, Ukraine; Research Institute of Medical Primatology, Sochi). No independent Western replication of any Pancragen finding has been published.
Pancragen (also sold under the AKS-P designation in commercial preparations) is a synthetic tetrapeptide with the sequence Lys-Glu-Asp-Trp (KEDW), developed by Professor Vladimir Khavinson and colleagues at the St. Petersburg Institute of Bioregulation and Gerontology. It is the pancreas-targeted member of the Khavinson bioregulator family, alongside the cardiac-targeted Cardiogen (AEDR), the vascular-targeted Vesugen (KED), and the pineal-targeted Epithalon (AEDG).
The design methodology was the same applied throughout the family: quantitative amino acid analysis of peptide extracts from bovine pancreatic tissue identified lysine, glutamic acid, aspartic acid, and tryptophan as characteristic short-chain components. The KEDW tetrapeptide was synthesized as a candidate active fraction. Note that the KEDW sequence extends the Vesugen KED tripeptide by a single tryptophan residue at the C-terminus, creating a structural relationship between the vascular and pancreatic bioregulators. Whether this C-terminal addition genuinely confers tissue specificity toward pancreatic over vascular tissue has not been systematically demonstrated in vivo.
The pancreas is the dual-function gland governing both endocrine (insulin/glucagon secretion from islets of Langerhans) and exocrine (digestive enzyme secretion from acinar cells) activity. Age-related pancreatic dysfunction is well documented: beta-cell mass and insulin secretory capacity decline with aging, contributing to the dramatic increase in type 2 diabetes prevalence after age 50. Pancragen's proposed utility is restoring gene expression in aging pancreatic cells, particularly in beta cells and acinar cells, to support insulin secretion and reduce age-related metabolic decline.
The compound is sold commercially in oral capsule form by the St. Petersburg Institute as a supplement for chronic pancreatitis and type 2 diabetes mellitus. The commercial product designation is Pancragen with recommended dosing of 1 to 2 capsules once or twice daily before meals for one month, repeated every 3 to 6 months. The capsules contain a preparation designated "peptide complex AKS-P" rather than the pure synthetic KEDW tetrapeptide used in research. The relationship between the supplement preparation and the research compound is not formally characterized in indexed literature.
Pancragen's proposed primary mechanism is epigenetic regulation of pancreatic gene expression through direct peptide-DNA interaction, following the same framework proposed for other Khavinson bioregulators.
The most detailed mechanistic characterization comes from the 2013 Khavinson et al. paper in Bulletin of Experimental Biology and Medicine (Khavinson, Durnova, Polyakova, Tolibova, Linkova, Kvetnoy, Kvetnaia, Tarnovskaya). Using human embryonic pancreatic cell cultures treated with Pancragen, the study demonstrated tissue-specific stimulation of differentiation factors, particularly CXCL12 and Hoxa3, with effects more pronounced in aged cultures than in young cultures. This aging-specific potentiation is proposed as a geroprotective mechanism: Pancragen preferentially restores gene expression in aged pancreatic cells whose regulatory regions have become more condensed and silenced.
The 2012 Khavinson et al. study in Advances in Gerontology characterized the broader transcription factor activation profile: Pancragen upregulated expression of PDX1, PAX6, PAX4, NGN3, FOXA2, and NKX2.2 in pancreatic cell cultures. These are the master regulators of pancreatic endocrine cell fate. PDX1 (pancreatic and duodenal homeobox 1) is the key beta-cell identity transcription factor; loss of PDX1 expression is associated with beta-cell dysfunction in type 2 diabetes. NGN3 drives endocrine progenitor specification. PAX6 and PAX4 regulate islet cell maturation. Restoring the expression of this entire transcription factor network is a mechanistically ambitious claim: it suggests Pancragen reactivates a developmental gene expression program in adult aging pancreatic cells.
Separately, the 2010 Khavinson et al. study (Bulletin of Experimental Biology and Medicine, Khavinson, Gapparov, Sharanova, Vasilyev, Ryzhak) characterized biological activity of the amidated form of the tetrapeptide (Lys-Glu-Asp-Trp-NH2) in rat and in vitro models, examining antiapoptotic marker expression. The amidated form is related to but distinct from the free-acid KEDW form. Studies found upregulation of MCl1 (an anti-apoptotic Bcl-2 family protein), Ki67 (a proliferation marker), and CD79alpha, alongside downregulation of p53, in pancreatic cell cultures. Upregulation of matrix metalloproteinases MMP2 and MMP9 was also noted. The antiapoptotic signature is consistent with beta-cell preservation.
The epigenetic mechanism is supported by the 2015 Ashapkin, Linkova, Khavinson, and Vanyushin paper (Biochemistry/Biokhimiia, Moscow) showing that Pancragen treatment was associated with alterations in methylation patterns at the PDX1, PAX6, and NGN3 gene promoter regions. Demethylation of gene promoters increases their accessibility to transcription factors, consistent with the gene expression findings.
Finally, Fedoreyeva et al. (2011) demonstrated that KEDW enters nuclei and interacts with double-stranded DNA in cell culture models, establishing cell penetration and DNA binding as properties of this compound class.
The melatonin connection introduced by the 2011 Korkushko human study deserves specific mention. That study found nocturnal melatonin production was 70% lower in elderly DM2 patients compared to healthy elderly controls. Melatonin receptors are expressed on pancreatic beta cells and melatonin regulates insulin secretion through MT1 and MT2 receptor signaling. The study's authors proposed that Pancragen may partially restore pancreatic function by acting on melatonin-insulin axis signaling, either directly or by normalizing circadian-related gene expression in islet cells. This mechanistic hypothesis has not been tested directly.
In the 33 elderly DM2 patients, Pancragen significantly decreased fasting glucose levels and glucose levels measured during standard oral glucose tolerance testing. Plasma insulin concentrations were reduced, and the insulin resistance index (HOMA-IR) was decreased. In patients who did not receive Pancragen, no changes in any carbohydrate metabolism index were observed during the study period.
The study also measured nocturnal melatonin production and found it was 70% lower in DM2 patients compared to healthy elderly controls, which the authors proposed as a mechanistic link between pineal decline, circadian disruption, and insulin resistance.
The study design has significant limitations. There was no placebo group; the comparator was untreated DM2 patients, not DM2 patients receiving a blinded placebo. The blinding status of outcome assessors is not stated. The study was conducted at the Institute of Gerontology, National Academy of Medical Sciences of Ukraine, which is affiliated with the Khavinson bioregulator research ecosystem. The route of Pancragen administration in this study is not specified in the available English abstract. These limitations mean the result, while published in an indexed peer-reviewed journal, cannot be interpreted with the confidence given to a double-blind randomized controlled trial.
The Korkushko 2011 study is the only indexed human study for any Khavinson bioregulator in a specific disease population with objective metabolic endpoints. The DM2 glucose reduction finding is meaningful if real. The critical limitations are the absence of blinding, the absence of a placebo arm, and the institutional affiliation. Independent replication in a Western setting with proper RCT design would transform this finding from a directional signal into validated clinical evidence. It has not been replicated in 14 years.
The 2014 Goncharova study characterized the baseline profile of aged rhesus monkey pancreatic function: old animals showed reduced glucose disappearance rate and higher insulin and C-peptide peaks at 5 and 15 minutes post-glucose challenge compared to young animals, demonstrating a primate model of age-related glucose intolerance. Pancragen administration at 50 mcg per animal per day for 10 days markedly increased the glucose disappearance rate and normalized plasma insulin and C-peptide dynamics in response to glucose. Effects partially persisted for 3 weeks after treatment discontinuation.
The 2015 comparative study against glimepiride in n=9 old rhesus females found that both treatments decreased basal glucose. Pancragen normalized insulin and C-peptide levels. Glimepiride produced a more expressed and delayed hypoglycemic effect and stimulated C-peptide secretion but had no significant effect on insulin secretion. The authors concluded Pancragen is effective and safe for correction of age-related endocrine pancreatic dysfunction, with a different pharmacological profile from glimepiride.
Rhesus monkey glucose metabolism is highly homologous to human. The n=9 study comparing Pancragen to an active comparator (glimepiride) is the most methodologically advanced study in the Pancragen literature, as it provides an active control rather than merely untreated comparison. However, the study was not blinded, n=9 is very small (5 vs. 4 animals), and randomization is not described.
The primate studies are the strongest preclinical evidence in the Pancragen portfolio because rhesus monkey glucose metabolism closely parallels human physiology and the comparison to glimepiride adds context. The characterization of Pancragen's pharmacological profile as distinct from but directionally similar to a sulfonylurea is biologically informative. The small n (9 animals), lack of blinding, and single-institution origin limit confidence. These studies represent a meaningful intermediate step between rodent models and human RCTs.
The 2013 Khavinson et al. study used human embryonic pancreatic cell cultures from donors of different ages. Pancragen stimulated expression of differentiation factors CXCL12 and Hoxa3 in a tissue-specific manner. The effect was more pronounced in aged cell cultures than in young cultures, consistent with the proposed geroprotective mechanism: Pancragen preferentially reactivates gene expression that has become silenced in aging pancreatic cells.
The 2012 Khavinson et al. study demonstrated upregulation of the full complement of pancreatic endocrine cell fate transcription factors: PDX1, NGN3, PAX6, PAX4, FOXA2, and NKX2.2. These are the master regulators that drive endocrine progenitor specification and beta-cell identity. PDX1 is the primary beta-cell identity factor and a direct therapeutic target in type 2 diabetes research. Simultaneously, antiapoptotic signals were enhanced (MCl1 upregulation, p53 reduction, Ki67 and PCNA proliferation marker increases), while MMP2 and MMP9 upregulation suggested remodeling activity.
The human embryonic pancreatic cell culture model used in the 2013 study is more proximal to clinical relevance than rodent models and provides a human cellular mechanistic basis for the differentiation factor findings. However, embryonic cells differ substantially from adult aging pancreatic cells, and the aging-cell comparisons within the study are culture-age comparisons rather than comparisons of cells from clinically aged donors.
The transcription factor activation data are the mechanistic foundation for the metabolic findings. Activating PDX1, NGN3, PAX6, and the other endocrine fate factors would, if translated to aging islets, plausibly restore functional beta-cell identity and insulin secretory competence. The aging-specific enhancement in cell culture is consistent with a geroprotective chromatin remodeling mechanism. The limitation is that cell culture findings in embryonic pancreatic tissue do not confirm that the same effects occur in aged adult islets with established type 2 diabetes pathology.
The 2007 Khavinson et al. study in diabetic rats found that oral Pancragen produced a significant hypoglycemic effect during treatment. Pancragen normalized the adhesion of mesenteric capillary endothelium, suggesting protective effects on vascular endothelial function in early diabetes. Notably, Pancragen did not affect capillary permeability, indicating a selective rather than broad effect on vascular biology. Homeostatic effects on glucose dynamics were observed.
The 2007 Kvetnoi et al. morphological study in streptozotocin-diabetic rats found that Pancragen treatment was associated with beneficial histological changes in pancreatic islet structure compared to untreated diabetic controls. The study's authors reported that Pancragen may support beta-cell preservation and islet architecture maintenance.
The streptozotocin model used in these studies primarily destroys beta cells through direct cytotoxic DNA damage, producing a type 1-like diabetes rather than the age-related, insulin-resistance-driven type 2 diabetes that is Pancragen's proposed clinical target. Effects seen in this model have limited direct relevance to type 2 diabetes pathology, though they establish that Pancragen has pharmacological activity on glucose metabolism in the context of severe beta-cell injury.
The rat diabetic model data provide mechanistic support for the human and primate findings but should not be over-interpreted. Streptozotocin-induced diabetes is a model of extreme, acute beta-cell destruction rather than the gradual, age-related beta-cell dysfunction of type 2 diabetes. That Pancragen shows activity even in this severe model is interesting, but the translatability to human type 2 diabetes is limited. The capillary adhesion normalization finding echoes Vesugen's endothelial biology and may reflect a shared mechanism via the shared KED motif.
The 2015 Ashapkin et al. study provided the most direct epigenetic evidence for the Pancragen mechanism. Treatment of pancreatic cell cultures with Pancragen was associated with alterations in DNA methylation at the promoter regions of PDX1, PAX6, and NGN3, the same master transcription factors whose expression was upregulated in the 2012 and 2013 functional studies. Specifically, partial demethylation of these promoters was observed, consistent with increased transcriptional accessibility.
Age-associated hypermethylation of these pancreatic transcription factor promoters is a recognized feature of beta-cell dysfunction and type 2 diabetes. PDX1 promoter methylation in particular is associated with reduced insulin gene expression and impaired glucose sensing in aging beta cells. The finding that Pancragen reduces methylation at these critical loci provides a coherent mechanistic link between the cell-penetrating epigenetic mechanism and the functional outcomes observed in glucose metabolism studies.
This 2015 paper also compared Pancragen's epigenetic effects with those of other Khavinson bioregulators (Epithalon, Vilon, and others), finding compound-specific methylation patterns consistent with the sequence-specific chromatin interaction model.
The DNA methylation data are mechanistically significant because PDX1 promoter hypermethylation is a real, well-characterized feature of aging beta-cell dysfunction in human type 2 diabetes. If Pancragen genuinely reverses this epigenetic modification in pancreatic cells, it would be addressing one of the root molecular causes of age-related beta-cell failure. The limitation is that the finding is from cell culture, the aging studied is culture aging rather than in vivo physiological aging, and the magnitude and durability of the demethylation effect in vivo is unknown.
Khavinson bioregulator peptide.
The 2011 Korkushko human study confirms that Pancragen was administered to 33 elderly DM2 patients with measurable glucose outcomes, making this the only Khavinson bioregulator with documented human metabolic data. The administration route in that study is not specified in the indexed abstract. Primate studies used 50 mcg per animal per day intramuscularly for 10 days. Commercial vendor protocols suggest 500 to 1000 mcg daily subcutaneously for 10 to 20 day cycles, but these extrapolations lack pharmacokinetic or dose-finding validation. Individuals with diabetes must monitor blood glucose and inform their physician before using Pancragen alongside any antidiabetic medication.
Within the Khavinson bioregulator family, Pancragen is distinctively positioned by its human metabolic data. Vesugen has Russian observational cardiovascular data but no specific metabolic endpoints. Epithalon has broader longevity claims in Russian elderly cohorts. Cardiogen has no human data at all. Pancragen's glucose-lowering mechanism connects it directly to the most therapeutically crowded space in all of metabolic medicine: type 2 diabetes. The comparison to GLP-1 agonists (semaglutide, tirzepatide), SGLT2 inhibitors, and metformin is stark: those compounds have Phase 3 RCT programs with tens of thousands of participants documenting not only glucose lowering but cardiovascular and renal outcome benefits. Pancragen has n=33 unblinded. For the Khavinson family, n=33 in humans is exceptional. In the context of type 2 diabetes therapeutics broadly, it is a hypothesis. The structural overlap between Pancragen (KEDW) and Vesugen (KED) raises the interesting question of whether the glucose effects and vascular effects represent overlapping or separable activities of the shared KED core.
Pancragen is the only Khavinson bioregulator with human safety signal data derived from an actual patient study. The 2011 Korkushko et al. study in 33 elderly DM2 patients reported no adverse effects attributable to Pancragen. This provides a minimal human safety baseline not available for Cardiogen or Vilon. However, the study was small, unblinded, conducted in a single elderly population, and did not characterize pharmacokinetics or organ function changes.
The most significant practical safety concern is the glucose-lowering effect. If Pancragen produces genuine hypoglycemic activity in elderly type 2 diabetes patients, combination with antidiabetic medications creates risk for hypoglycemia. The 2011 study conducted Pancragen alongside the patients' existing care, but did not specify whether antidiabetic medications were adjusted or continued unchanged. The 2015 primate study compared Pancragen to glimepiride, a sulfonylurea with known hypoglycemic risk. The comparison showed Pancragen produced a different pharmacological profile (normalizing insulin and C-peptide without the pronounced delayed hypoglycemic effect of glimepiride), but this does not mean combination is safe. Any glucose-affecting compound combined with established antidiabetic therapy requires blood glucose monitoring.
In the rat diabetic model studies (Khavinson et al., 2007, Bulletin of Experimental Biology and Medicine; Kvetnoi et al., 2007, Bulletin of Experimental Biology and Medicine), oral and subcutaneous Pancragen produced significant hypoglycemic effects without reported adverse effects on organ histopathology. The 2007 Kvetnoi study examined pancreatic morphology in streptozotocin-diabetic rats and reported beneficial histological changes, not toxicity.
No chronic administration safety data in humans exist. No organ toxicity has been reported in any published animal study. The compound is composed entirely of amino acids present in normal human physiology. Tetrapeptides are expected to be rapidly metabolized by peptidases in blood and tissue.
No drug interactions have been formally studied. The amidated form (Lys-Glu-Asp-Trp-NH2) studied in some experiments differs chemically from the free-acid KEDW typically sold as research peptide; their safety profiles are distinct and should not be conflated.
Pancragen occupies a unique position in the Khavinson bioregulator family: it is the only one with published indexed human data in a specific disease population, yet it remains far from the controlled trial evidence that would be required to make any clinical recommendation.
The 2011 Korkushko human study in 33 elderly type 2 diabetes patients is a genuine, indexed, peer-reviewed finding with objectively measured metabolic outcomes. Fasting glucose improved. HOMA-IR improved. Untreated patients showed no change. This is more than narrative clinical claims, which is what most Khavinson bioregulators offer. The rhesus monkey comparison to glimepiride adds pharmacological context. The mechanistic chain from PDX1 promoter demethylation to beta-cell transcription factor activation to insulin secretion is biologically coherent and grounded in recognized type 2 diabetes pathophysiology.
The critical limitations are equally clear. The human study was not blinded and had no placebo arm. It came from an institution embedded in the Khavinson bioregulator research ecosystem. It involved only 33 DM2 patients. It has not been independently replicated in 14 years, despite the widespread availability of Pancragen as a commercial supplement targeting exactly the population studied. The gap between a promising, uncontrolled n=33 finding and established clinical evidence is not small.
For anyone with type 2 diabetes considering Pancragen, the glucose-lowering finding makes medical supervision and blood glucose monitoring obligatory, not optional. Combining Pancragen with existing antidiabetic medication without dose adjustment creates real hypoglycemia risk. This is not a compound to use as a self-directed supplement on top of an insulin or sulfonylurea regimen without informing a treating physician.
Pancragen is the most clinically compelling Khavinson bioregulator studied in this series to date, and it remains a compound that has not progressed to the controlled trials its human signal justifies.
For research and educational purposes only · Not medical advice · Consult a qualified physician before any human use